Facebook
X
LinkedIn
Forward17011, AML in older adults: Are outcomes age dependent?
AML disease heterogeneity and diverse patient fitness levels have led to debate over therapeutic options for older adults. New research is clarifying the risks and benefits of treatment choices for the increasing number of patients over age 60 who are considering induction therapy and consolidative HCT. Using an interactive, case study-based format, presenters will discuss patient comorbidities, disease factors and assessment tools that influence treatment decision-making.
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Enduring Material for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1 hours of participation for continuing education for allied health professionals.
Questions?
If you have any questions regarding this activity, contact Nicole Heino, continuing education manager, Education and Training, NMDP/Be The Match at (800) 526-7809 ext. 4811, or email [email protected].
This webinar series is sponsored by NMDP/Be The Match and partially funded through a National Comprehensive Cancer Network education intervention grant. For information on the study, contact Ellen Denzen, M.S., Health Services Research, NMDP/Be The Match at [email protected].
Target Audience
Learning Objectives
At the conclusion of this activity, I will be able to:
- Apply evidence-based patient- and disease-specific prognostic factors at diagnosis to identify potential treatment options for patients with AML
- Compare the risks and benefits of therapeutic options, including HCT, for older patients with AML
- Cite recent clinical trial results and the impact of treatment timing and disease status on outcomes for older patients
- Use patient education resources to support the needs of patients and caregivers in understanding treatment choices for older patients
Fred Appelbaum, M.D. (moderator)
Fred Hutchinson Cancer Research Center
Laura C. Michaelis, M.D.
Medical College of Wisconsin, Froedrert Hospital
James Foran, M.D., FRCPC
Mayo Clinic – Jacksonville
| Name | Company | Role |
| Sergio Giralt, MD | Celgene, Sanofi, Jazz, Takeda, Amgen | Research, Advisory Board |
| Laura Michaelis, MD | Incyte, Celgene, Pfizer | Consultant, Stock Owner |
| Navneet Majhail, MD | Anthem Inc., Sanofi | Consultant, Speaker |
| Jackie Foster, MPH, RN | Pfizer | Stock Owner |
| James Foran, MD | Novartis, Takeda, Agios | Advisory Board, Research |
| Fred Applebaum, MD | Adaptive Biotechnologies, Amgen, Celator | Consultant |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.